Overview of the drug development pipeline for diabetic retinopathy
Diabetic retinopathy (DR) is a disease that occurs in diabetes patients. This disease damages the retina, which is light-sensitive by nature. Diabetic retinopathy is a serious eyesight-threatening disease and if left untreated, it can cause blindness in the patient. Diabetes is known to damage blood vessels that are present in the retina. Diabetic retinopathy occurs when blood vessels leak blood and other fluids causing swelling of the retinal tissue, resulting in blurred vision. The chances of occurrence of diabetic retinopathy is high in patients affected with diabetes for a very long time. There are two types of diabetic retinopathy, namely non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). A common cause of diabetic retinopathy is a high concentration of aldose reductase, an increase in vascular endothelial growth factor levels, and abnormalities in platelets. Monotherapy is emerging as the most effective treatment approach towards the treatment of diabetic retinopathy.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for diabetic retinopathy. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of diabetic retinopathy. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Acucela
- Boehringer Ingelheim
- Coherus BioSciences
Therapeutic assessment of the drug development pipeline for diabetic retinopathy by route of administration
- Intravitreal
- Ocular
- Oral
- Subcutaneous
- Unknown
The intravitreal route of administration (ROA) involves the application of the drug directly into the eye and in the ocular method, the drug molecules are administered into the eye in the form of a liquid drop solution, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for diabetic retinopathy by therapy
- Monotherapy
- Unknown
According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for diabetic retinopathy are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the gene therapy molecules in the various development stages for diabetic retinopathy?
- What are the companies that are currently involved in the development of drug molecules for diabetic retinopathy?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.